MXCT at a glance
MAXCYTE, INC. (MXCT, SEC CIK 1287098) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 12, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding MAXCYTE, INC. (MXCT) shares worth $26.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $21.0M
- −5.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $26.0M · −5 vs prior quarter
- Latest 8-K
- Aug 12, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No Risk Factors section provided in the submitted filing text
- No new or changed quarterly risks identifiable from the provided excerpt
- $10 million share-repurchase authorization announced May 12, 2026
- 1,313,066 shares repurchased at average $1.13 through June 30, 2026
AI summary of the MXCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation posted August 12, 2026 for investor communications and conferences
- Exhibit 99.2 contains management’s latest corporate messaging and strategy context
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $7.3M, down 15% YoY; core revenue $6.5M, down 21%, signaling continued operating softness
- SPL revenue rose to $0.8M from $0.3M, driven by royalties up 150% to $0.8M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected Class II directors Patrick Balthrop, Cynthia Collins, and Stanley Erck
- Cynthia Collins received the strongest support, with 46,886,614 votes for and 5,602,591 withheld
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq minimum bid-price deficiency cured after 10 consecutive business days at or above $1.00
- Compliance period ran May 27–June 9, 2026
AI summaries of MXCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MXCT
Don't miss the next MXCT filing
- Alerts as it files. A push when MXCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MXCT, by share count.
- Ask anything. An AI agent that reads every MXCT filing and answers with sources.
MXCT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Erck Stanley C | A | Jun 17, 2026 | 49,579 | - |
| Collins Cynthia | A | Jun 17, 2026 | 30,421 | - |
| DOUGLAS RICHARD | A | Jun 17, 2026 | 30,421 | - |
| Al-Wakeel Yasir B. | A | Jun 17, 2026 | 30,421 | - |
| Al-Wakeel Yasir B. | A | Jun 17, 2026 | 49,579 | - |
| Hemrajani Rekha | A | Jun 17, 2026 | 30,421 | - |
| Hemrajani Rekha | A | Jun 17, 2026 | 49,579 | - |
| Brooke William W | A | Jun 17, 2026 | 30,421 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $22.2M | $21.0M |
| Gross Profit | - | $31.5M | $26.8M |
| Operating Income | - | -$51.2M | -$51.9M |
| Net Income | - | -$41.1M | -$44.6M |
| Gross Margin | - | 141.9% | 127.9% |
| Op. Margin | - | -230.5% | -247.6% |
| Net Margin | - | -184.8% | -213.0% |
| Balance Sheet | |||
| Total Assets | $268.3M | $239.5M | $202.5M |
| Equity | - | $206.3M | $171.5M |
| ROE | - | -19.9% | -26.0% |
| Per Share | |||
| EPS | - | $-0.39 | $-0.42 |
| Cash Flow | |||
| Operating CF | - | -$27.6M | -$34.4M |
| CapEx | $3.7M | $1.7M | $1.8M |
Source: XBRL data in MAXCYTE, INC. (MXCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MXCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $26.0M |
| Q1 2026 | 25 | $19.4M |
| Q4 2025 | 23 | $45.3M |
| Q3 2025 | 23 | $48.3M |
| Q2 2025 | 24 | $71.8M |
| Q1 2025 | 20 | $63.4M |
| Q4 2024 | 18 | $72.0M |
| Q3 2024 | 16 | $41.6M |
- Millennium Management+1.16M (+2698%)
- Two Sigma Investments+854.8K (+141%)
- AQR Capital Management+661.6K (+54%)
- Citadel Advisors LLC+523.2K (+157%)
- Goldman Sachs Group+82.9K (+7%)
- BlackRock−5.74M (-65%)
- State Street Corp−1.68M (-76%)
- Vanguard Portfolio Management LLC−628.8K (-71%)
- Northern Trust−534.8K (-67%)
- BNY Mellon−323.6K (-80%)
- D.E. Shaw & Co−200.5K
- Invesco Ltd−119.2K
- T. Rowe Price Group−51.5K
- Wells Fargo & Co−38.2K
- Prudential Financial−15.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MXCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| SC 13D | Aug 4, 2026 | - | - | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| SC 13D | May 14, 2026 | - | - | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | Apr 17, 2026 | - | - | - |
| 4 | Apr 10, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 10-K | Mar 25, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
| 8-K | Mar 20, 2026 | - | - | - |
| 4 | Mar 19, 2026 | - | - | - |
| SC 13G | Feb 5, 2026 | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
MXCT SEC filings: frequently asked questions
Which institutions hold MXCT stock?
As of June 30, 2026, the largest MAXCYTE, INC. (MXCT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($5.0 million), Morgan Stanley ($4.5 million), BlackRock ($3.8 million), Renaissance Technologies LLC ($2.4 million), AQR Capital Management ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MXCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42. The figures come from the XBRL data in the 10-K.
What did MXCT report in its latest 8-K?
MAXCYTE, INC. (MXCT) filed an 8-K on August 12, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation posted August 12, 2026 for investor communications and conferences.
What are the latest MXCT SEC filings?
MAXCYTE, INC. (MXCT) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 12, 2026 and a Form 4 insider filing on June 22, 2026.
What is MXCT's SEC CIK number?
MAXCYTE, INC. (MXCT)'s SEC Central Index Key (CIK) is 1287098. EDGAR lists every MXCT filing under that number.
Ask anything about MXCT
The research agent reads MXCT's filings, financials, insider trades and 13F holders, then answers with sources.